English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/97305
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Toxicological and pharmacological evaluation, antioxidant, ADMET and molecular modeling of selected racemic chromenotacrines {11-amino-12-aryl-8,9, 10,12-tetrahydro-7H-chromeno[2,3-b]quinolin-3-ols} for the potential prevention and treatment of Alzheimer's disease

AuthorsOset-Gasque, María Jesús; González, María Pilar; Pérez-Peña, Javier; García-Font, Nuria; Romero, Alejandro ; Pino, Javier del; Ramos, Eva; Hadjipavlou-Litina, Dimitra; Soriano, Elena ; Chioua, Mourad ; Samadi, Abdelouahid ; Raghuvanshi, Dushyant S.; Singh, Krishna N.; Marco-Contelles, José
Keywords11-Amino-12-aryl-8,9,10,12-tetrahydro-7Hchromeno[
2,3-b]quinolin-3-ols
Tacrine analogs
Toxicity
EeAChE
hBuChE
Kinetic analysis
Inhibition mechanism
Antioxidant
Neuroprotection
Molecular modeling
ADMET
Alzheimer’s disease
Issue Date2014
PublisherElsevier
CitationEuropean Journal of Medicinal Chemistry 74: 491- 501 (2014)
AbstractThe pharmacological analysis of racemic chromenotacrines (CT) 1-7, bearing the 11-amino-12-aryl-8,9,10,12-tetrahydro-7H-chromeno[2,3-b]quinolin-3-ol ring skeleton, in a series of experiments targeted to explore their potential use for the treatment of Alzheimer's disease (AD), is reported. The toxicological evaluation showed that among all these chromenotacrines, CT6 is much less hepatotoxic than tacrine in a range of concentrations from 1 to 300 μM, measured as cell viability in HepG2 cells. Moreover, CT6 did not significantly increase lactate dehydrogenase, aspartate transaminase, and alanine transaminase release in HepG2 cells. Besides, CT6 treatment exerts a high protective effect against the lipid peroxidation induced after H2O2-treated SH-SY5Y cells, in a concentration-dependent manner. CT6 showed an excellent antioxidant profile in the AAPH test, and protects against the decrease in cell viability induced by respiratory chain inhibitors (Oligomicyn A/Rotenone) and NO donors in neuronal cultures. This effect could be due to a mixed antiapoptotic and antinecrotic neuroprotective effect at low and intermediate CT6 concentrations, respectively. CT1-7 are potent and selective inhibitors of EeAChE in the submicromolar range. CT3 [IC50 (EeAChE) = 0.007 ± 0.003 μM], and CT6 [IC50 (EeAChE) = 0.041 ± 0.001 μM] are the most potent AChE inhibitors. Kinetic studies on the non-toxic chromenotacrine CT6 showed that this compound behaves as a non-competitive inhibitor (Ki = 0.047 ± 0.003 μM), indicating that CT6 binds at the peripheral anionic site, a fact confirmed by molecular modeling analysis. In silico ADMET analysis showed also that CT6 should have a moderate BBB permeability. Consequently, non-toxic chromenotacrine CT6 can be considered as an attractive multipotent molecule for the potential treatment of AD. © 2014 Elsevier Masson SAS. All rights reserved.
URIhttp://hdl.handle.net/10261/97305
DOI10.1016/j.ejmech.2013.12.021
Identifiersdoi: 10.1016/j.ejmech.2013.12.021
issn: 0223-5234
isbn: 1768-3254
Appears in Collections:(IQOG) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.